CoChat
Sign Up
Cited by 58

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

The Cell Type–Specific 5hmC Landscape and Dynamics of Healthy Human Hematopoiesis and TET2 -Mutant Preleukemia

Nakauchi, Yusuke, Azizi, Armon, Thomas, Daniel, Corces, M. Ryan, Reinisch, Andreas, Sharma, Rajiv, Cruz Hernandez, David, Köhnke, Thomas, Karigane, Daiki, Fan, Amy, Martinez-Krams, Daniel, Stafford, Melissa, Kaur, Satinder, Dutta, Ritika, Phan, Paul, Ediriwickrema, Asiri, McCarthy, Erin, Ning, Yuhong, Phillips, Tierney, Ellison, Christopher K., Guler, Gulfem D., Bergamaschi, Anna, Ku, Chin-Jen, Levy, Samuel, Majeti, Ravindra·2022·Blood Cancer Discovery
DOI 10.1158/2643-3230.bcd-21-0143

Published version of a preprint

Open this paper in CoChat — free account

Abstract

The conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) is a key step in DNA demethylation that is mediated by ten–eleven translocation (TET) enzymes, which require ascorbate/vitamin C. Here, we report the 5hmC landscape of normal hematopoiesis and identify cell type–specific 5hmC profiles associated with active transcription and chromatin accessibility of key hematopoietic regulators. We utilized CRISPR/Cas9 to model TET2 loss-of-function mutations in primary human hematopoietic stem and progenitor cells (HSPC). Disrupted cells exhibited increased colonies in serial replating, defective erythroid/megakaryocytic differentiation, and in vivo competitive advantage and myeloid skewing coupled with reduction of 5hmC at erythroid-associated gene loci. Azacitidine and ascorbate restored 5hmC abundance and slowed or reverted the expansion of TET2-mutant clones in vivo. These results demonstrate the key role of 5hmC in normal hematopoiesis and TET2-mutant phenotypes and raise the possibility of utilizing these agents to further our understanding of preleukemia and clonal hematopoiesis. Significance: We show that 5-hydroxymethylation profiles are cell type–specific and associated with transcriptional abundance and chromatin accessibility across human hematopoiesis. TET2 loss caused aberrant growth and differentiation phenotypes and disrupted 5hmC and transcriptional landscapes. Treatment of TET2 KO HSPCs with ascorbate or azacitidine reverted 5hmC profiles and restored aberrant phenotypes. This article is highlighted in the In This Issue feature, p. 265

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2643-3230.bcd-21-0143

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 39

  1. Tahiliani, 2009, Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1, Science, 324, 930, 10.1126/science.1170116 · DOI · Paper page
  2. Ito, 2010, Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification, Nature, 466, 1129, 10.1038/nature09303 · DOI · Paper page
  3. Hahn, 2013, Dynamics of 5-hydroxymethylcytosine and chromatin marks in Mammalian neurogenesis, Cell Rep, 3, 291, 10.1016/j.celrep.2013.01.011 · DOI
  4. Cimmino, 2011, TET family proteins and their role in stem cell differentiation and transformation, Cell Stem Cell, 9, 193, 10.1016/j.stem.2011.08.007 · DOI
  5. Huang, 2014, Connections between TET proteins and aberrant DNA modification in cancer, Trends Genet, 30, 464, 10.1016/j.tig.2014.07.005 · DOI
  6. Ko, 2015, DNA methylation and hydroxymethylation in hematologic differentiation and transformation, Curr Opin Cell Biol, 37, 91, 10.1016/j.ceb.2015.10.009 · DOI
  7. Ko, 2010, Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2, Nature, 468, 839, 10.1038/nature09586 · DOI · Paper page
  8. Jung, 2015, An LSC epigenetic signature is largely mutation independent and implicates the HOXA cluster in AML pathogenesis, Nat Commun, 6, 8489, 10.1038/ncomms9489 · DOI
  9. Farlik, 2016, DNA methylation dynamics of human hematopoietic stem cell differentiation, Cell Stem Cell, 19, 808, 10.1016/j.stem.2016.10.019 · DOI · Paper page
  10. Zhang, 2016, DNMT3A and TET2 compete and cooperate to repress lineage-specific transcription factors in hematopoietic stem cells, Nat Genet, 48, 1014, 10.1038/ng.3610 · DOI · Paper page
  11. Yamazaki, 2015, TET2 mutations affect non-CpG island DNA methylation at enhancers and transcription factor–binding sites in chronic myelomonocytic leukemia, Cancer Res, 75, 2833, 10.1158/0008-5472.CAN-14-0739 · DOI · Paper page
  12. Solary, 2014, The ten-eleven translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases, Leukemia, 28, 485, 10.1038/leu.2013.337 · DOI
  13. Stroud, 2011, 5-Hydroxy­methylcytosine is associated with enhancers and gene bodies in human embryonic stem cells, Genome Biol, 12, R54, 10.1186/gb-2011-12-6-r54 · DOI
  14. Amouroux, 2016, De novo DNA methylation drives 5hmC accumulation in mouse zygotes, Nat Cell Biol, 18, 225, 10.1038/ncb3296 · DOI
  15. Tsagaratou, 2014, Dissecting the dynamic changes of 5-hydroxymethylcytosine in T-cell development and differentiation, Proc Natl Acad Sci U S A, 111, E3306, 10.1073/pnas.1412327111 · DOI
  16. Song, 2017, 5-Hydroxymethylcytosine signatures in cell-free DNA provide information about tumor types and stages, Cell Res, 27, 1231, 10.1038/cr.2017.106 · DOI
  17. Chiu, 2019, Prognostic implications of 5-hydroxymethylcytosines from circulating cell-free DNA in diffuse large B-cell lymphoma, Blood Adv, 3, 2790, 10.1182/bloodadvances.2019000175 · DOI
  18. Yang, 2019, 5-Hydroxymethylcytosines in circulating cell-free DNA reveal vascular complications of type 2 diabetes, Clin Chem, 65, 1414, 10.1373/clinchem.2019.305508 · DOI
  19. Minor, 2013, Ascorbate induces ten-eleven translocation (Tet) methylcytosine dioxygenase-mediated generation of 5-hydroxymethylcytosine, J Biol Chem, 288, 13669, 10.1074/jbc.C113.464800 · DOI · Paper page
  20. Cimmino, 2017, Restoration of TET2 function blocks aberrant self-renewal and leukemia progression, Cell, 170, 1079, 10.1016/j.cell.2017.07.032 · DOI · Paper page
  21. Bejar, 2014, TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients, Blood, 124, 2705, 10.1182/blood-2014-06-582809 · DOI
  22. Cui, 2020, A human tissue map of 5-hydroxymethylcytosines exhibits tissue specificity through gene and enhancer modulation, Nat Commun, 11, 1, 10.1038/s41467-020-20001-w · DOI
  23. Weissmann, 2012, Landscape of TET2 mutations in acute myeloid leukemia, Leukemia, 26, 934, 10.1038/leu.2011.326 · DOI
  24. Oceguera-Yanez, 2016, Engineering the AAVS1 locus for consistent and scalable transgene expression in human iPSCs and their differentiated derivatives, Methods, 101, 43, 10.1016/j.ymeth.2015.12.012 · DOI
  25. Yan, 2017, Distinct roles for TET family proteins in regulating human erythropoiesis, Blood, 129, 2002, 10.1182/blood-2016-08-736587 · DOI
  26. Wang, 2020, Loss of Tet2 affects platelet function but not coagulation in mice, Blood Science, 2, 129, 10.1097/BS9.0000000000000055 · DOI
  27. Smith, 2010, Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value, Blood, 116, 3923, 10.1182/blood-2010-03-274704 · DOI
  28. Selimoglu-Buet, 2015, Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia, Blood, 125, 3618, 10.1182/blood-2015-01-620781 · DOI
  29. An, 2015, Acute loss of TET function results in aggressive myeloid cancer in mice, Nat Commun, 6, 10071, 10.1038/ncomms10071 · DOI
  30. Li, 2017, 5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers, Cell Res, 27, 1243, 10.1038/cr.2017.121 · DOI
  31. Hilton, 2015, Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers, Nat Biotechnol, 33, 510, 10.1038/nbt.3199 · DOI
  32. Rasmussen, 2019, TET2 binding to enhancers facilitates transcription factor recruitment in hematopoietic cells, Genome Res, 29, 564, 10.1101/gr.239277.118 · DOI · Paper page
  33. Quivoron, 2011, TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis, Cancer Cell, 20, 25, 10.1016/j.ccr.2011.06.003 · DOI · Paper page
  34. Mazumdar, 2015, Leukemia-associated cohesin mutants dominantly enforce stem cell programs and impair human hematopoietic progenitor differentiation, Cell Stem Cell, 17, 675, 10.1016/j.stem.2015.09.017 · DOI
  35. Reilly, 2021, 5-Azacytidine transiently restores dysregulated erythroid differentiation gene expression in TET2-deficient erythroleukemia cells, Mol Cancer Res, 19, 451, 10.1158/1541-7786.MCR-20-0453 · DOI
  36. Zhang, 2008, Model-based analysis of ChIP-Seq (MACS), Genome Biol, 9, R137, 10.1186/gb-2008-9-9-r137 · DOI · Paper page
  37. Chen, 2008, Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice, Proc Natl Acad Sci U S A, 105, 11105, 10.1073/pnas.0804226105 · DOI · Paper page
  38. Ji, 2008, An integrated software system for analyzing ChIP-chip and ChIP-seq data, Nat Biotechnol, 26, 1293, 10.1038/nbt.1505 · DOI
  39. Liang, 2012, Normalization of ChIP-seq data with control, BMC Bioinform, 13, 1, 10.1186/1471-2105-13-199 · DOI

Cited by

See all 58

Metadata

Authors
Nakauchi, Y., Azizi, A., Thomas, D., Corces, M. R., Reinisch, A., Sharma, R., Cruz Hernandez, D., Köhnke, T., Karigane, D., Fan, A., Martinez-Krams, D., Stafford, M., Kaur, S., Dutta, R., Phan, P., Ediriwickrema, A., McCarthy, E., Ning, Y., Phillips, T., Ellison, C. K., Guler, G. D., Bergamaschi, A., Ku, C.-J., Levy, S., & Majeti, R.
Affiliations
  • 1Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, California.
  • 11Bluestar Genomics Inc., San Mateo, California.
ORCID
Venue
Blood Cancer Discovery
Publisher
American Association for Cancer Research (AACR)
Published
2022-06-02
Volume
3
Issue
4
Pages
346-367
ISSN
  • 2643-3230
  • 2643-3249
DOI
10.1158/2643-3230.bcd-21-0143
Cited by
58
References
13
Language
en
Funders
NIH (1R01HL142637, 1R01CA251331)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review